Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group
Pediatric Blood & Cancer2014Vol. 62(4), pp. 629–636
Citations Over TimeTop 10% of 2014 papers
Elliot Stieglitz, Ashley F. Ward, Robert B. Gerbing, Todd A. Alonzo, R.J. Arceci, Y. Lucy Liu, Peter D. Emanuel, Brigitte C. Widemann, Jennifer W. Cheng, Nalini Jayaprakash, Frank M. Balis, Robert P. Castleberry, Nancy Bunin, Mignon L. Loh, Todd M. Cooper
Abstract
Administration of tipifarnib in the window setting followed by HSCT in patients with newly diagnosed JMML was safe and yielded a 51% initial response rate as a single agent, but failed to reduce relapse rates or improve long-term overall survival.
Related Papers
- → Molecular basis of juvenile myelomonocytic leukemia(2010)59 cited
- → Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia(2009)50 cited
- → Is Juvenile Myelomonocytic Leukemia (Jmml) A Myelodysplastic or A Myeloproliferative Disease?(1999)2 cited
- Allogeneic Hematopoietic Stem Cell Transplantation in Juvenile Myelomonocytic Leukemia(2005)
- [Molecular biology of juvenile myelomonocytic leukemia (JMML)].(2010)